True Wealth Design LLC Has $36,000 Holdings in Bruker Co. (NASDAQ:BRKR)

True Wealth Design LLC increased its holdings in Bruker Co. (NASDAQ:BRKR) by 4,636.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 521 shares of the medical research company’s stock after purchasing an additional 510 shares during the quarter. True Wealth Design LLC’s holdings in Bruker were worth $36,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC grew its position in shares of Bruker by 21.4% in the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after buying an additional 2,521,904 shares during the last quarter. Marshall Wace LLP boosted its holdings in Bruker by 127.8% in the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock valued at $88,666,000 after acquiring an additional 779,549 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Bruker during the 2nd quarter valued at approximately $36,472,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Bruker by 1,933.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company’s stock worth $28,331,000 after purchasing an additional 390,057 shares during the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Bruker by 123.6% in the 2nd quarter. AQR Capital Management LLC now owns 555,468 shares of the medical research company’s stock worth $35,444,000 after purchasing an additional 307,021 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien bought 100,000 shares of the stock in a transaction dated Monday, November 18th. The stock was bought at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 28.30% of the company’s stock.

Bruker Stock Performance

BRKR opened at $57.95 on Monday. The company has a market cap of $8.79 billion, a price-to-earnings ratio of 27.86, a PEG ratio of 3.89 and a beta of 1.20. The company’s fifty day moving average price is $60.63 and its two-hundred day moving average price is $64.01. Bruker Co. has a 1-year low of $48.07 and a 1-year high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The company’s revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 EPS. On average, analysts expect that Bruker Co. will post 2.4 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Monday, December 2nd will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker’s payout ratio is currently 9.62%.

Analyst Ratings Changes

Several research firms have recently weighed in on BRKR. Wells Fargo & Company decreased their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Barclays lowered their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Citigroup cut their target price on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. TD Cowen dropped their price target on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $79.36.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.